Kornimate/medical-research-clean huggingface dataset:
facial expression recognition and mirror neurons in parkinson's disease

Conditions: Parkinson's Disease

Summary: after few years of evolution, patients with parkinson's disease may develop apathy, with different degrees of severity. apathy is characterized by a loss of interest for the others and for activities. the lack of social interactions in these patients may be due to an impairment in decoding emotional facial expression. indeed, facial expression recognition, which is necessary to understand other's emotional state, requires a subclinical facial mimicking of the expression observed. yet, one of the clinical signs of pd is amimia. this study aims to determinate if there is a facial mimicry disorder in pd ( parkinson's disease )patients with emotional facial expression (efe) recognition impairment, compared to healthy control subjects. we also want to know if this facial mimicry disorder is primary (subtended by facial mobility impairment, that is to say amimia) or secondary (related to the mirror neuron systems that allows us to activate similar neural networks when observing and feeling a specific emotion)

20 patients with an idiopathic parkinson's disease + 20 paired healthy volunteers (on sex, age, and education) after inclusion, patients are evaluated two times: they are studied without medication (med off) and with medication (stim on) in a randomized order. the 2 evaluations should be spaced out 15 days to one month (j0 and j+15d) healthy subjects have only one visit j0 (inclusion and emotional facial expression recognition tests are made at the same time)

Eligibility criteria:
inclusion criteria: * patients with idiopathic parkinson's disease according to ukpdsbb criteria - men or women aged between 18 to 75 years * free from any visio-perceptive disorder (visual acuity and vitec) * affiliated to national health system * having given their informed consent --healthy controls * men or women aged between 18 to 75 years * free from any visio-perceptive disorder (visual acuity and vitec) * affiliated to national health system * having given their informed consent exclusion criteria: * with dementia or with significant dysexecutive disorder (mms \<24, mattis\< 130) * with fluctuations (\<5 levodopa intakes / day) * with severe depression (bdi \> 27) * with psychiatric comorbidities (hallucinations, psychos) evaluated with l'unified parkinson's disease rating scale part i (updrs part i =0) * with faces processing disorder (benton \< 39) * pregnant * treatment with deep brain stimulation * under guardianship * in excluding period for another study --healthy controls * suffering of neurological or psychiatric evolutive condition * with severe depression (bdi \> 27) * with faces processing disorder (benton \< 39) * pregnant * in excluding period for another study

Keywords: emotional facial expression apathy mirror neurons
brain development research program

Conditions: Brain Disorders; Aicardi Syndrome

Summary: dr. elliott sherr and his collaborators at university of california, san francisco (ucsf) are studying the genetic causes of disorders of cognition and epilepsy, in particular disorders of brain development that affect the corpus callosum, such as aicardi syndrome, as well as two additional brain malformations, polymicrogyria and dandy-walker malformation. the goal of the investigators' research is to use a better understanding of the underlying genetic causes as a foundation to develop better treatments for these groups of patients.

we are studying both the genetics and clinical features of these disorders. we hope to understand the problems faced by individuals with these disorders as well as their causes. in the future, we hope to develop therapies that are geared specifically for individuals based on the underlying biology. to participate in the study, you will be asked to provide a copy of the magnetic resonance imaging (mri) documenting agenesis corpus callosum (acc), polymicrogyria (pmg), or dandy-walker malformation (dwm), clinical information, and saliva or blood samples from the affected individual and from the parents. please see contact information and our webpage below.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of agenesis or dysgenesis of the corpus callosum, polymicrogyria, or dandy-walker malformation * should be confirmed by an mri (magnetic resonance imaging) of the brain exclusion criteria: * fully formed but hypoplastic corpus callosum

Keywords: agenesis corpus callosum polymicrogyria dandy-walker brain malformation autism epilepsy mental retardation mri agenesis of the corpus callosum (complete or partial) confirmed by a brain mri. aicardi syndrome.
impact normative extension

Conditions: Brain Concussion

Summary: the researchers want to find out more about a standalone software application, impact online and how it relates to other commonly used tests of memory, attention and reaction time. impact online is a computer-based neurocognitive test for concussion management. the test was designed to help measure the effects of concussion on cognitive processes (for example, memory, attention, brain speed) and visual functioning.


Eligibility criteria:
inclusion criteria: 1. age: 60-80 2. primary english speaking or fluent in english. 3. currently does not reside in a skilled nursing facility. 4. currently not suffering from a concussion or being treated for a concussion, unless enrolled in the subgroup discriminative validity. 5. no known physical, neurological, behavioral or psychological impairment that would affect their ability to perform the test. 6. hearing or vision impairments that have not been corrected within normal limits. 7. a score of 24 or greater on the mmse (mini-mental state examination). exclusion criteria: 1. english is not their primary language nor are they proficient in the english language. 2. currently resides in a skilled nursing facility. 3. currently suffering from a concussion or being treated for a concussion, unless enrolled in the subgroup discriminative validity. 4. known physical, neurological, behavioral, or psychological impairment that would affect their ability to take or complete the test. 5. hearing or vision impairments that would affect their ability to perform the test. 6. score of 23 or below on the mmse(mini-mental state examination).
expanding rapid ascertainment networks of schizophrenia families in taiwan

Conditions: Schizophrenia

Summary: this proposal responds to request for applications rfa-mh-08-131, which seeks applications that propose to enrich pre-existing resources for schizophrenia in the nimh human genetics initiative and to apply genomic methods to further our understanding of the molecular etiology of the disorder. the overarching aims of this proposal are to quickly and cost-effectively ascertain a large sample of trio families affected by schizophrenia, and to discover causal variants for the disorder in the first family-based genome-wide association study (gwas) of the disorder. in taiwan, there is no such kind of policy to support this kind of gwas study as it is a very expensive study, including collecting large family samples and genome-wide snp scanning. the investigators, thus, collaborate with professor ming t, tsuang and his intended subcontracted researchers to apply for this project. the investigators, the research team in taiwan, will collect 3800 trio families (11400 subjects) of schizophrenia. the investigators will meet the overarching goals of this project by accomplishing several specific aims, as follows: 1) rapidly ascertain schizophrenia trio families from taiwanese clinical ascertainment sites; 2) supplement nimh genetics initiative collections by sending all clinical data and biomaterials to the appropriate repositories; 3) assess the association of schizophrenia with a genome-wide panel of single-nucleotide polymorphisms (snps) and their constituent haplotypes; 4) analyze quantitative schizophrenia phenotypes such as age at onset ; 5) perform a genome-wide survey for copy-number variations related to schizophrenia; 6) test for gene-gene interactions (epistasis); and 7) test for gene-environment interactions, such as the well-established effect of season of birth.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of schizophrenia and their parents,and parents are still alive exclusion criteria: * person with mental retardation * persons with epilepsy * alcohol or substance abuse combined * in combination with other organic brain damage syndrome
open versus intact capsule proton pump inhibitors for the treatment of marginal ulcers

Conditions: Marginal Ulcer

Summary: the goal of this clinical trial is to identify the most effective way to take acid-blocking medications to treat stomach ulcers in patients who have undergone gastric bypass surgery. the main questions it aims to answer are: * is taking an acid-blocking medication by opening the capsule and only taking the contents of the capsule (open-capsule) more or less effective than taking the capsule as a whole (intact-capsule) for treating ulcers in patients who have a history of gastric bypass surgery? * does taking the open versus intact medication decrease the number of procedures and complications from untreated ulcers? participants with ulcers will be instructed to take acid-blocking medications (called proton-pump inhibitors) either by opening the capsule and taking only the contents or by taking the capsule whole. these medications are the gold standard for treatment of stomach ulcers. participants will be asked to undergo an upper endoscopy (egd) every 3 months to monitor the healing of the ulcers. researchers will compare how quickly the ulcers heal depending on which way the medications are taken (opened up or as a whole).

marginal ulcers (ulcers formed at the surgery site between the stomach and the intestines) are a common complication of bariatric surgery, ranging in frequency from 0.6-25% of patients. furthermore, roughly 17% of patients with marginal ulcers require repeat procedures or surgery for severe complications such as bleeding, perforation, stricture, and fistulas. proton pump inhibitors (ppis), which act by block acid secretion from the stomach, are the gold standard for treatment of ulcers. there is limited data showing that opening the ppi capsule and taking only the contents greatly improves healing of marginal ulcers after gastric bypass surgery. this is likely due to the much smaller stomach, faster passage through the stomach and decreased ability of the intact ppi medication to be broken down and absorbed. this would be the first clinical trial to confirm whether this is true, which would support all patients who get ulcers after gastric bypass surgery to be treated with open-capsule ppi medications.

Eligibility criteria:
inclusion criteria: * subjects diagnosed with marginal ulceration post-gastric bypass on upper endoscopy exclusion criteria: * refusal to start ppi medication or current open-capsule ppi use at the time of diagnosis of the marginal ulcer

Keywords: marginal ulcer bariatric surgery gastric bypass open capsule
postoperative hypoxia and body position

Conditions: Postoperative Complications; Abdominal Surgery; Hypoxia

Summary: the study aims at investigate whether the oxygen partial pressure is improved in the prone position postoperative after abdominal surgery. included are 50 adults operated with abdominal surgery. the intervention is turning from supine to prone position and then back to supine position while measuring whether an improvement occurs in oxygen saturation and oxygen partial pressure, or not.

postoperative hypoxia complicates 30% - 50% of abdominal surgeries. the cause of postoperative restrictive lung function and hypoxia is unknown. previous studies report that oxygen partial pressure decreases by an average of 2 kpa after abdominal surgery, while carbon dioxide partial pressure is unchanged and vital capacity decreases by 35%. patients are operated and treated in the post anesthesia care unit in the supine position. the study aims at investigate whether the oxygen partial pressure is improved in the prone position postoperative after abdominal surgery or not. inclusion: 50 adults operated with abdominal surgery. exclusion: esophageal surgery, abdominal vessel surgery. decline participation. intervention: turning from supine to prone position and then back to supine position again. primary outcome: change in oxygen saturation and oxygen partial pressure. secondary outcome: change in carbondioxide partial pressure procedures: partial blood gas is taken before surgery. on the day of surgery or the day after: starting in supine position with continuous measurements of oxygen saturation from pulse oximetry, transcutaneous carbon-dioxide partial pressure and blood gas. then turning to prone position and then back to supine position.

Eligibility criteria:
inclusion criteria: * being operated within 2 in the abdomen because of upper gastrointestinal surgery, colorectal surgery, urological surgery or emergency surgery * must be able to turn from supine position to prone position in the bed exclusion criteria: * esophageal surgery, abdominal vessel surgery. * decline participation.
initial development and dissemination of oc-go

Conditions: Obsessive-Compulsive Disorder

Summary: the clinical component of phase i application development examines the clinical utility, feasibility, and functionality of the oc-go application via an 8-month pilot trial consisting of 50 standard cbt sessions augmented with oc-go in ocd-diagnosed children who are receiving treatment through the pediatric ocd treatment programs in the ucla division of child and adolescent psychiatry

this project seeks to refine and assess oc-go, a hipaa-compliant web-based clinician portal and patient-side mobile application designed to increase patient adherence to evidence-based treatment (ebt) for obsessive compulsive disorder (ocd), a common and impairing condition, and provider ability to effectively implement ebts. oc-go allows clinicians to create and push tailored assignments to patients on their mobile devices with an optimized user interface that includes patient accountability and support features. accordingly, patients can be guided to do assignments by themselves between sessions with increased fidelity over the course of treatment. once therapy assignments are created and shared to a crowd-sourced and curated public library, any clinician can assign any task to any patient for homework or in-session use with one touch. use of oc-go is expected to increase patient engagement, compliance, treatment efficiency, dissemination of ebts, and therapist confidence and expertise.

Eligibility criteria:
inclusion criteria: * children receiving exposure based cbt through the ucla child ocd, anxiety and tic disorders clinic or pediatric ocd intensive outpatient program and their parents exclusion criteria: * none

Keywords: exposure response prevention web-based application
treatment of common bile duct stones

Conditions: Common Bile Duct Stone

Summary: abstract introduction: common bile duct (cbd) stone is a common clinical situation, especially in asia area. laparotomy and laparoscopic surgical procedure are often used for treatment. this study compares outcomes of different surgical procedures treating for the disease. methods/design: this is a prospective, randomized, controlled multicenter trial with three treatment arms. one group underwent laparoscopic cholecystectomy (lc) + laparoscopic cbd exploration (lcbde) + intraoperative endoscopic nasobiliary drainage enbd + primary closure of cbd. the other underwent preoperative endoscopic retrograde cholangiopancreatography (ercp) and subsequent lc and the third arm underwent laparoscopic cholecystectomy (lc) + laparoscopic cbd exploration (lcbde) + primary closure of cbd. the duration of the entire trial is two years including prearrangement, follow-up and analyses. discussion: despite the fact plenty evidences provided by meta-analyses suggests that these approaches would appear comparable. it is hopeful to fully address which would be the better approach with this rct design.


Eligibility criteria:
inclusion criteria: * patients with age between 18 - 80 years. * patients diagnosed with gallstones. * patients diagnosed with common bile duct stone by one of the three exam (us、mrcp and ct). * patients diagnosed with common bile duct stone by intro-operative cholangiography or transcystic exploration. * patients understood the trial and accepted one of the three managements. exclusion criteria: * combined with mirizzi syndrome and intrahepatic bile duct stones * previous est/endoscopic retrograde cholangiopancreatography (ercp) or percutaneous transhepatic biliary drainage (ptbd) * history of upper abdominal surgery. * serious heart, brain, lung, metabolic diseases history. * pregnant women. * unwillingness or inability to consent for the study.

Keywords: common bile duct stone; laparoscopic common bile duct exploration; ercp;
sleep restriction therapy (srt) for sleep problems in children with autism

Conditions: Autism Spectrum Disorder (ASD); Autism

Summary: the purpose of this open label trial is to examine the acceptability, tolerability, and feasibility and preliminary effectiveness of sleep restriction therapy for sleep problems in children with autism spectrum disorder (asd). treatment will be delivered via secure telemedicine platform and consist of parent-training in delivering the intervention.


Eligibility criteria:
inclusion criteria: * diagnosed with autism spectrum disorder (based on history, review of available medical records including diagnostic testing, e.g., autism diagnostic observation schedule and/or autism diagnostic interview-revised, childhood autism rating scale-2) * with sleep disturbances (based on clinical interview, and sleep disturbance scale for children score \> 38) * stable pre-existing medication plans for at least 2 weeks * no planned changes in psychosocial and biomedical interventions during the intervention * an english-speaking parent able to consistently participate in study procedures * reside in california, usa exclusion criteria: * parent or child diagnosed with severe psychiatric disorder or unstable medical problem * children with active seizures or epilepsy * primary sleep disorder is a circadian rhythm sleep-wake disorder, as determined by the sleep interview and children's chronotype questionnaire. * current active trial of sleep restriction therapy or history of an adequate trial of sleep restriction therapy.

Keywords: autism sleep intervention
dose ranging study of lunsekimig compared with placebo-control in adult participants with moderate-to-severe asthma

Conditions: Asthma

Summary: this is a phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with sc lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.


Eligibility criteria:
inclusion criteria: * a physician-diagnosed moderate-to-severe asthma for ≥12 months based on gina guidelines steps 4 and 5 * participants with existing treatment with moderate-to-high doses of ics therapy for in combination with at least 1 but no more than 2 additional controller medications at least 3 months with a stable dose ≥1 month prior to visit 1 * at least 1 asthma exacerbation in the past year, with at least one exacerbation occurring while on treatment with moderate to high doses of ics therapy * acq-5 score more than 1.5 at screening (visit 1) exclusion criteria: * chronic obstructive or other lung diseases (eg, copd, idiopathic pulmonary fibrosis, etc) which may impair lung function, or another diagnosed pulmonary or systemic disease. * current smoker or former smoker with cessation within 6 months of screening or history of \>10 pack-years. active vaping of any products and/or marijuana smoking within 6 months of screening. * participants who experience a deterioration of asthma that results in emergency treatment or hospitalization, or treatment with systemic steroids within 1 month prior to the screening * participants who have experienced an upper or lower respiratory tract infection within the 4 weeks prior to screening * for participants on chronic ocs use for the maintenance treatment of asthma: history of a serious infection requiring hospitalization within the past 12 months prior to randomization (visit 2). * participants with active tuberculosis (tb), latent tb, a history of incompletely treated tb, suspected extrapulmonary tb infection, or who are at high risk of contracting tb (such as close contact with individuals with active or latent tb) or received bacillus calmette-guérin (bcg)-vaccination within 12 weeks prior to screening * severe concomitant illness that would in the investigator's opinion inhibit the participant's participation in the study, including for example, but not limited to, hypertension, renal disease, neurological conditions, heart failure and pulmonary disease * the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
subclinical cardiac involvement in patients with inflamatory bowel disease

Conditions: Inflammatory Bowel Diseases

Summary: aim of the study is to determine the prevelance of subclinical cardiac involvement in patients with inflamatory bowel disease.

cardiovascular manifestations in patients with ibd mostly occur as immune-related consequences and include the following: pericarditis, myocarditis, venous and arterial thromboembolism, left ventricle impairment, arrhythmias and conduction disorders and valvulopathy . the prevalence of classical cardiovascular risk factors is relatively lower in ibd patients than in the general population . however, the risk of coronary heart disease is higher in ibd patients . the pathophysiology of cardiac involvement may be systemic inflammation for prolonged periods that can cause platelet aggregation and endothelial dysfunction leading to the development of atherosclerosis and cvd . the chronic inflammatory condition found in ibd is the key element in the pathogenesis of arrhythmias. in ibd, inflammation causes mitral and aortic valvulopathies , excess tnf-α causes the thickening and shortening of the leaflets, resulting in regurgitation . medications of ibd may be involved in pathogenesis of cardiac involvement as follows 5-asa and its derivatives can cause myopericarditis . atrial fibrillation and prolonged qt interval may occur during azathioprine use . cyclosporine is associated with increased risk of hypertension, arrhythmias, acute coronary syndrome, and heart failure . biological molecules are associated with increased arrhythmogenic risks . primary preventive measures of arterial thromboembolism include maintaining the remission, strict control of cardiovascular risk factors . the diagnostic modalities to find out cardiac involvement include; the 12-lead electrocardiogram . transthoracic echocardiography which represent the method of choice to evaluate both systolic and diastolic functions of lt ventricle. methodology: all patints will be subjected to the followings : full history taking including * duration of illness * symptoms of disease activity * symptoms of extraintestinal manifestation * family history of cardiac disease * history of traditional cardiovascular risk factors diabetes,hypertension,dyslipidaemia,cigarette smooking) * therapeutic history examination * body mass index. * vital signs( pulse,blood pressure,temperature). * cardiac examination. labaratory investigations * complete blood count - serum electrolytes * esr - crp * lipid profile - blood glucose level * tsh,t3,t4 ecg * ischaemic changes * any type of arrythmia * prolonged qt interaval holter ecg echocardiography * systolic and diastolic dysfunctions * wall motion abnormalities * valvular heart disease * ventricular hypertrophy * atrial and ventricular dimentions

Eligibility criteria:
inclusion criteria: * inflamatory bowel disease patients without previous history of cardiac disease. exclusion criteria: * patients known to have previous cardiac disease.